Blueprint Medicines (BPMC) Scheduled to Post Quarterly Earnings on Tuesday

Blueprint Medicines (NASDAQ:BPMCGet Rating) will issue its quarterly earnings data before the market opens on Tuesday, May 3rd. Analysts expect the company to announce earnings of ($1.80) per share for the quarter. Blueprint Medicines has set its FY 2022 guidance at EPS.

Blueprint Medicines (NASDAQ:BPMCGet Rating) last issued its earnings results on Wednesday, February 16th. The biotechnology company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.28). The company had revenue of $107.00 million for the quarter, compared to analysts’ expectations of $104.14 million. Blueprint Medicines had a negative net margin of 357.66% and a negative return on equity of 31.04%. The company’s revenue was up 213.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.53) earnings per share. On average, analysts expect Blueprint Medicines to post $-7 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Shares of Blueprint Medicines stock opened at $61.38 on Wednesday. Blueprint Medicines has a one year low of $53.26 and a one year high of $117.86. The stock has a market cap of $3.63 billion, a PE ratio of -5.59 and a beta of 0.95. The stock has a 50 day moving average of $63.86.

In other Blueprint Medicines news, insider Ariel Hurley sold 761 shares of the stock in a transaction on Thursday, March 3rd. The stock was sold at an average price of $60.27, for a total value of $45,865.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark Alan Goldberg acquired 5,000 shares of the stock in a transaction dated Thursday, March 3rd. The stock was acquired at an average price of $59.98 per share, for a total transaction of $299,900.00. The disclosure for this purchase can be found here. Insiders have sold 10,575 shares of company stock valued at $677,614 in the last three months. 3.34% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of BPMC. Morgan Stanley grew its holdings in Blueprint Medicines by 763.6% during the 2nd quarter. Morgan Stanley now owns 535,446 shares of the biotechnology company’s stock valued at $47,098,000 after buying an additional 473,445 shares in the last quarter. LPL Financial LLC purchased a new position in Blueprint Medicines during the third quarter valued at $239,000. Barclays PLC increased its holdings in Blueprint Medicines by 64.6% in the 4th quarter. Barclays PLC now owns 72,560 shares of the biotechnology company’s stock valued at $7,772,000 after acquiring an additional 28,481 shares during the last quarter. Cubist Systematic Strategies LLC lifted its stake in Blueprint Medicines by 1,296.3% in the 4th quarter. Cubist Systematic Strategies LLC now owns 8,699 shares of the biotechnology company’s stock worth $932,000 after purchasing an additional 8,076 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Blueprint Medicines by 1.3% during the 4th quarter. Legal & General Group Plc now owns 52,934 shares of the biotechnology company’s stock valued at $5,670,000 after purchasing an additional 656 shares during the last quarter.

Several research firms recently weighed in on BPMC. Morgan Stanley cut their price target on Blueprint Medicines from $111.00 to $92.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 1st. Guggenheim increased their target price on Blueprint Medicines from $120.00 to $122.00 in a research note on Monday, January 3rd. Wedbush restated an “outperform” rating and issued a $126.00 price target on shares of Blueprint Medicines in a research note on Monday, February 28th. HC Wainwright dropped their price objective on Blueprint Medicines from $135.00 to $100.00 and set a “buy” rating on the stock in a research report on Thursday, February 17th. Finally, Stifel Nicolaus lifted their target price on shares of Blueprint Medicines from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Friday, March 4th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Blueprint Medicines presently has a consensus rating of “Buy” and an average price target of $106.45.

About Blueprint Medicines (Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.

Recommended Stories

Earnings History for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.